NCT03923270View on ClinicalTrials.gov

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 6, 2019

Primary Completion Date

June 1, 2023

Study Completion Date

December 31, 2025

Conditions
Small Cell Lung Cancer Extensive StageSmall-cell Lung Cancer
Interventions
DRUG

Durvalumab

Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.

DRUG

Tremelimumab

Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.

DRUG

Olaparib Pill

Participants in arm C will be self-administer 300 mg of Olaparib orally.

RADIATION

Thoracic Radiotherapy

Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions

DRUG

Tremelimumab

Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER